Olmesartán/Amlodipino Stada (Amlodipine, Olmesartan)

Olmesartan/Amlodipine is indicated for the management of hypertension, a condition characterized by elevated arterial blood pressure.

• Essential hypertension: lowers systolic and diastolic pressure to target levels.
• Secondary hypertension: assists in controlling blood pressure when caused by underlying disorders.
• High cardiovascular risk patients: contributes to blood pressure management to reduce the risk of stroke and myocardial infarction.

• Olmesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, promoting arterial vasodilation. The combined effect results in reduced peripheral resistance and lowered blood pressure.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially after the first dose.
• Peripheral edema: swelling of ankles or feet.
• Flushing or warmth sensation.
• Fatigue or generalized weakness.
• Palpitations or increased heart rate.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Allergic reactions: rash, itching, or severe skin eruptions.
• Myocardial infarction: rare but reported in susceptible individuals.
• Renal impairment: worsening kidney function in predisposed patients.

Before initiating therapy, clinicians should consider the following precautions:

• Monitor blood pressure: adjust dosage if target levels are not achieved.
• Assess renal function: especially in patients with chronic kidney disease.
• Check electrolytes: potassium and sodium levels may be affected.
• Avoid use in patients with known hypersensitivity to either component.
• Pregnancy: only use if clearly needed after risk‑benefit assessment.
• Store at room temperature: keep in the original container, protect from moisture and light.

Olmesartan/Amlodipine may interact with several medicines. Review the following interactions carefully.

Major Interactions (Avoid)

• ACE inhibitors or aliskiren: increased risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics: potential for dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may raise amlodipine plasma concentrations.
• NSAIDs: can blunt antihypertensive effect and affect renal function.
• Lithium: concurrent use may raise lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: additive blood‑pressure lowering effect.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce amlodipine efficacy.
• Diuretics: may cause electrolyte disturbances, especially potassium.
• Grapefruit juice: can increase amlodipine exposure, requiring monitoring.